Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
The originally published version of this Article contained errors in Figure 4. In panel b, the square and diamond labels associated with the uppermost survival curve were incorrectly displayed as ‘n’ and ‘u’, respectively. These errors have now been corrected in both the PDF and HTML versions of the...
Main Authors: | Pengju Wang, Xiaozhu Li, Jiwei Wang, Dongling Gao, Yuenan Li, Haoze Li, Yongchao Chu, Zhongxian Zhang, Hongtao Liu, Guozhong Jiang, Zhenguo Cheng, Shengdian Wang, Jianzeng Dong, Baisui Feng, Louisa S Chard, Nicholas R Lemoine, Yaohe Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-02205-9 |
Similar Items
-
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
by: Pengju Wang, et al.
Published: (2017-11-01) -
Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime
by: Zhe Zhang, et al.
Published: (2020-08-01) -
The capability of heterogeneous γδ T cells in cancer treatment
by: Wenyi Yan, et al.
Published: (2023-11-01) -
Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
by: Yangyang Jia, et al.
Published: (2023-02-01) -
Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
by: Yaohe Wang, et al.
Published: (2022-05-01)